<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115824">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01674868</url>
  </required_header>
  <id_info>
    <org_study_id>FLAN SpauldingRH</org_study_id>
    <nct_id>NCT01674868</nct_id>
  </id_info>
  <brief_title>Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke</brief_title>
  <acronym>FLAN</acronym>
  <official_title>Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spaulding Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spaulding Rehabilitation Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will recruit 16-25 subjects  to assess the feasibility of replicating the
      FLAME study (Chollet, et al. Lancet 2011), an randomized controlled trial (RCT) that
      assessed the effect of fluoxetine vs placebo on motor recovery after ischemic stroke,  in an
      American sample of post-acute stroke patients. This trial will in addition examine the
      effect of treatment with fluoxetine versus placebo on concurrent deficits in language and
      hemispatial attention, and will evaluate the durability of observed effects in all 3
      domains. The results of this pilot trial will be used to develop power estimates for a
      larger trial and to evaluate recruitment and intervention completion rates for subjects in
      an American post-acute environment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Scale (FMMS)</measure>
    <time_frame>baseline to 45 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in FMMS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Scale (FMMS)</measure>
    <time_frame>baseline to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in FMMS score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Scale (FMMS)</measure>
    <time_frame>baseline to 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in FMMS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Aphasia Battery</measure>
    <time_frame>baseline to 45 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in Western Aphasia Quotient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Aphasia Battery</measure>
    <time_frame>baseline to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in Western Aphasia Quotient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Aphasia Battery</measure>
    <time_frame>baseline to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in Wester Aphasia Quotient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inattention Test (BIT)</measure>
    <time_frame>baseline to 45 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in BIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inattention Test (BIT)</measure>
    <time_frame>baseline to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in BIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inattention Test (BIT)</measure>
    <time_frame>baseline to 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in BIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence Measure</measure>
    <time_frame>baseline to discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in FIM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 20 mg fluoxetine daily for 90 days starting at day 5-10 after stroke.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take one pill  daily for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>20 mg daily for 90 days starting day 5-10 after stroke.</description>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subjects will take one pill po daily for 90 days.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and older

          -  Ischemic infarction within the past 10 days

          -  Fluent in English

          -  May require assistance of surrogate to give consent

          -  Functional Communication Measure &gt;=1 for patients with inattention

          -  Functional Communication Measure &gt;=3 for patients with aphasia

          -  NIH Stroke Scale &lt; 20 on admission to Spaulding

          -  Able to follow directions and participate in 2 hrs of testing with short breaks

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Hemianopsia

          -  Active depression on admission to Spaulding

          -  Taking an SSRI or other medication likely to have adverse interaction with an SSRI

          -  Resides too far away to return for follow-up testing

          -  Unable to give consent and no surrogate available
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randie Black-Schaffer, MD</last_name>
      <phone>617-573-7106</phone>
      <email>rblackschaffer@partners.org</email>
    </contact>
    <investigator>
      <last_name>Yong-Tae Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Mazwi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>August 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spaulding Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Randie Black-Schaffer MD</investigator_full_name>
    <investigator_title>Medical Director, Stroke Program</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>recovery</keyword>
  <keyword>fluoxetine</keyword>
  <keyword>aphasia</keyword>
  <keyword>neglect</keyword>
  <keyword>motor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
